Back to Awarded Treatment Trials
Awarded Trial: 10T-002
Grant ID
10T-002
Illness
Schizophrenia
Primary Drug/Intervention
N-acetyl cysteine
Primary Dosage
3000 mg/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Breier
Sample Size
60
Duration of Study Period for Each Subject
6 months
Outcome Measurements
N/A
Results
No significant differences between NAC and placebo on any region of interest examined including cortical white matter volume, and thickness of temporal, frontal and parietal cortices. NAC, compared to placebo, significantly improved PANSS total symptoms, PANSS disorganization and CGI severity, but not positive and negative symptoms, functioning or cognition.
Publication
Breier A, Liffick E, Hummer TA, et al. Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. https://doi.org/10.1016/j.schres.2018.03.012
Link
N/A
PI Name
Alan Breier
Degree
MD
Center
Department of Psychiatry
Institution
Indiana University School of Medicine
Address
Psychiatry Building, 1111 W. 10th Street
City or Town
Indianapolis
State or Province
IN
Zip or Postal Code
46202
Country
U.S.A.
Email Address
abreier@iupui.edu